Marker Therapeutics Inc (MRKR)

[GS1]

CFO in small biotech has much larger role than just number crunching especially when it comes down to funding many small biotechs won't make it to phase III no matter how good their product is and that is why they look for partner to advance drug.
If TPIV decides to go it alone then they will need more capital and company recently said they need about 7 million for phase II 40 patient trial and bassed on that estimate if they decide to go with 300 patient phase III trial they would need 10 times money i.e 70 million for phase III and to get drug to market which can be done without much dilution in NASDAQ. This is assuming they won't encounter any issues. Most of trial costs attributed to failures and if drug never fails the actuals cost is in the range of 100-200 mil. This is just my opinion.